Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers

August 5, 2024 |  

Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.

OCP white paper

It reveals:

  • The critical role of OCPs in treatment decisions and cost management
  • Opportunities for manufacturers to share pre-approval information
  • Key evidence needs for pathway inclusion
  • Optimal communication strategies with OCP stakeholders
  • Future trends in pathway comprehensiveness

Essential reading for oncology market access professionals looking to stay ahead in an evolving landscape and gain actionable insights on communicating your oncology product’s value and optimizing its pathway positioning.

>> VISIT THE WHITE PAPER DOWNLOAD PAGE TO VIEW THE ARTICLE

This content was provided by Genesis Research Group

Company Details

Genesis Research Group logo

Genesis Research Group

Email
Website

 Latest Content from  Genesis Research Group 

Genesis Research Insights & Evidence webinar 20 Oct: Reserve your place!

Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar ‘Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to…

Leading pharmaceutical executive Jennifer Fillman joins evidence-based solution provider Genesis Research as Chief Financial Officer

International health economics and outcomes research (HEOR) and real-world evidence (RWE) organization Genesis Research has announced the appointment of Jennifer Fillman as its new Chief Financial Officer. Prior to joining…

Genesis Research and Syapse combine forces to offer RWE and data to oncology innovators

Genesis Research is delighted to announce a strategic partnership with Syapse®, combining the expertise and resources of both companies to better serve clients that are developing new oncology innovations.

Genesis Research and Clinical Outcomes Solutions announce innovative partnership

International Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) organization Genesis Research is delighted to announce an exciting new partnership with Clinical Outcomes Assessment (COA) specialist Clinical Outcomes…

Genesis Research Acquires Market Access Transformation

Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),…

ISPOR 2022: a retrospective

Genesis Research – an introduction

Ensuring fit-for-purpose real-world data to generate real-world evidence with Susan Oliveria

Genesis Research at the World EPA Congress 2022

GHO Capital Acquires Genesis Research

GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the acquisition of Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes…